STAT+: Sanofi, Regeneron expand partnership after Dupixent success

Sanofi and Regeneron have re-upped their collaboration pact, aiming to build on the blockbuster success of the drug Dupixent.

Image from the linked report: STAT+: Sanofi, Regeneron expand partnership after Dupixent success.Credit: STAT Thumbnail shown with attribution and outbound source link; VINI does not claim ownership or republish the original article body. Image source Image shown with attribution and an outbound source link; VINI does not claim ownership or republish the original article body.

Reading time1 min

coverage / Wire report

References1 public source

Open references

Reader responseScience

Right of reply / send a tip

SupportDonate

Fund future reporting

Why it mattersScience

Sanofi and Regeneron have re-upped their collaboration pact, aiming to build on the blockbuster success of the drug Dupixent.

What to know1 source

Check the original link, updates, and responses when a detail is contested.

Keep readingmedical

Open topic or search related wording such as records, sources, agencies, dates, and locations.

Vinita Duniphin Science Wire report

What happened

According to STAT’s source item, STAT+: Sanofi, Regeneron expand partnership after Dupixent success, Sanofi and Regeneron have re-upped their collaboration pact, aiming to build on the blockbuster success of the drug Dupixent.

Context

The development sits in VINI’s Science file for readers following research, health, climate, space, medicine, and scientific institutions. The original report is linked so readers can check the source account, follow later updates, and compare new coverage against the first published record. The source item is dated 2026-10-01T06:16:27+00:00.

What to watch

Open questions include whether primary sources issue follow-up statements, whether local or market impacts become clearer, and whether additional reporting changes the timeline or adds material context.

Source

Primary source: STAT+: Sanofi, Regeneron expand partnership after Dupixent success via STAT. VINI cites and links the source; it does not reproduce the publisher’s full article text without rights clearance.

Keep following

This file can keep developing

vininews.com uses reader tips, public records, right-of-reply requests, corrections, and follow-up reporting to keep important stories current.

SubscribeGet the next update Send recordsShare documents or leads RespondRequest comment or reply DonateSupport reporting costs

Support and subscriptions never buy coverage, placement, suppression, or corrections.

This VINI report keeps the original publisher link available and does not republish third-party article bodies without rights clearance. 1 reference listed.

Reader comments

Moderated discussion

Account access

Comments are open to authenticated approved accounts, screened for spam and abuse, and published only after newsroom moderation unless editors change the story control.

Loading comments.

No approved comments yet.

Substantive, civil comments can be submitted by approved account holders.